Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab in Hypermutated HR+ Breast Cancer
NCT03608865Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Sep 2017
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in breast cancer, sponsored by Yonsei University. Primary endpoint: Objective Response Rate up to 4 years. Started Sep 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03608865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608865.